Blood group does not correlate with disease severity in patients with Fabry disease (alpha-galactosidase A deficiency)

Gabor E. Linthorst; Claudia C. Folman; Johannes M. F. G. Aerts; Carla E. M. Hollak

doi:https://doi.org/10.1016/S1079-9796(03)00163-3

Blood group does not correlate with disease severity in patients with Fabry disease (alpha-galactosidase A deficiency)

Gabor E. Linthorst, Claudia C. Folman, Johannes M. F. G. Aerts, Carla E. M. Hollak

Research output: Contribution to journal › Article › Academic › peer-review

9 Citations (Scopus)

Abstract

Blood groups B and P1 are substrates for the lysosomal enzyme alpha-galactosidase A. Therefore, patients with alpha-Gal A deficiency and blood groups B or P1 may exhibit more severe disease. In 48 Fabry patients distribution of blood group was not different from that in the Dutch population. No patient had blood group B. Clinical symptoms did not differ between bloodgroup P1 or P2 patients. We conclude that blood groups B and P1 are not overrepresented in Dutch Fabry patients. Blood group PI is not correlated with more severe disease and cannot be considered a significant risk factor. (C) 2003 Elsevier Inc. All rights reserved

Original language	English
Pages (from-to)	324-326
Journal	Blood cells, molecules & diseases
Volume	31
Issue number	3
DOIs	https://doi.org/10.1016/S1079-9796(03)00163-3
Publication status	Published - 2003

Access to Document

https://doi.org/10.1016/S1079-9796(03)00163-3

Cite this

@article{a32ce3bd016f4ed98942abf4fe1b83e0,

title = "Blood group does not correlate with disease severity in patients with Fabry disease (alpha-galactosidase A deficiency)",

abstract = "Blood groups B and P1 are substrates for the lysosomal enzyme alpha-galactosidase A. Therefore, patients with alpha-Gal A deficiency and blood groups B or P1 may exhibit more severe disease. In 48 Fabry patients distribution of blood group was not different from that in the Dutch population. No patient had blood group B. Clinical symptoms did not differ between bloodgroup P1 or P2 patients. We conclude that blood groups B and P1 are not overrepresented in Dutch Fabry patients. Blood group PI is not correlated with more severe disease and cannot be considered a significant risk factor. (C) 2003 Elsevier Inc. All rights reserved",

author = "Linthorst, {Gabor E.} and Folman, {Claudia C.} and Aerts, {Johannes M. F. G.} and Hollak, {Carla E. M.}",

year = "2003",

doi = "https://doi.org/10.1016/S1079-9796(03)00163-3",

language = "English",

volume = "31",

pages = "324--326",

journal = "Blood cells, molecules & diseases",

issn = "1079-9796",

publisher = "Academic Press Inc.",

number = "3",

}

TY - JOUR

T1 - Blood group does not correlate with disease severity in patients with Fabry disease (alpha-galactosidase A deficiency)

AU - Linthorst, Gabor E.

AU - Folman, Claudia C.

AU - Aerts, Johannes M. F. G.

AU - Hollak, Carla E. M.

PY - 2003

Y1 - 2003

N2 - Blood groups B and P1 are substrates for the lysosomal enzyme alpha-galactosidase A. Therefore, patients with alpha-Gal A deficiency and blood groups B or P1 may exhibit more severe disease. In 48 Fabry patients distribution of blood group was not different from that in the Dutch population. No patient had blood group B. Clinical symptoms did not differ between bloodgroup P1 or P2 patients. We conclude that blood groups B and P1 are not overrepresented in Dutch Fabry patients. Blood group PI is not correlated with more severe disease and cannot be considered a significant risk factor. (C) 2003 Elsevier Inc. All rights reserved

AB - Blood groups B and P1 are substrates for the lysosomal enzyme alpha-galactosidase A. Therefore, patients with alpha-Gal A deficiency and blood groups B or P1 may exhibit more severe disease. In 48 Fabry patients distribution of blood group was not different from that in the Dutch population. No patient had blood group B. Clinical symptoms did not differ between bloodgroup P1 or P2 patients. We conclude that blood groups B and P1 are not overrepresented in Dutch Fabry patients. Blood group PI is not correlated with more severe disease and cannot be considered a significant risk factor. (C) 2003 Elsevier Inc. All rights reserved

U2 - https://doi.org/10.1016/S1079-9796(03)00163-3

DO - https://doi.org/10.1016/S1079-9796(03)00163-3

M3 - Article

C2 - 14636646

SN - 1079-9796

VL - 31

SP - 324

EP - 326

JO - Blood cells, molecules & diseases

JF - Blood cells, molecules & diseases

IS - 3

ER -